Skip to main content
NewslettersWatchlist

Centerra Gold Inc(CG-T)
TSX

Today's Change
Real-Time Last Update

Optic Neuritis (Ophthalmology) Drugs Pipeline Guide 2021 - ResearchAndMarkets.com

Business Wire - Fri Sep 17, 2021

The "Optic Neuritis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Optic Neuritis pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 5 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Repot Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

Companies Mentioned

  • Accure Therapeutics SL
  • EnhanX Biopharm Inc
  • Japan Innovative Therapeutics Inc
  • Meta-IQ ApS
  • Mitochon Pharmaceuticals Inc
  • Noveome Biotherapeutics Inc
  • ReNetX Bio
  • SanBio Co Ltd

     

Key Topics Covered:

Introduction

Optic Neuritis - Overview

Optic Neuritis - Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Optic Neuritis - Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Optic Neuritis - Companies Involved in Therapeutics Development

  • Accure Therapeutics SL
  • EnhanX Biopharm Inc
  • Japan Innovative Therapeutics Inc
  • Meta-IQ ApS
  • Mitochon Pharmaceuticals Inc
  • Noveome Biotherapeutics Inc
  • ReNetX Bio
  • SanBio Co Ltd

Optic Neuritis - Drug Profiles

Optic Neuritis - Dormant Projects

Optic Neuritis - Discontinued Products

Optic Neuritis - Product Development Milestones

Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/r/am4dlh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

market news
Premarket: Stocks rise ahead of Big Tech earnings
A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 5, 2024. REUTERS/Andrew Kelly/ File photo
market news
The close: Stocks higher with major corporate earnings on tap
A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 5.
inside the market
If pension funds can’t see the case for investing in Canada, why should you?
Ian McGugan
market news
The close: Nasdaq, S&P 500 tumble as Netflix, chip stocks drag; TSX gains
Traders work on the floor of the New York Stock Exchange during afternoon trading on April 9.
market news
The close: TSX edges higher as metal prices rally
A Toronto Stock Exchange ticker is seen at The Exchange Tower in Toronto on Thursday, August 18 2011.
market news
The close: TSX snaps losing streak as mining shares rebound
Traders work on the floor of the New York Stock Exchange during afternoon trading on April 9.
report on business
Parkland shares jump as investor signals it’s open to a sale
The Ultramar gas station on Broadview Ave. and Bater Ave. is photographed on Mar 26, 2024. Fred Lum/The Globe and Mail
globe investor
Trump media stock plunges, extending recent losses Trump Media
Former President Donald Trump attends trial for jury selection at Manhattan Criminal Court on Monday, April 15, 2024 in New York City.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).